Serum BDNF levels before treatment predict SSRI response in depression

Area of Science:

• Neuroscience
• Psychiatry
• Biochemistry

Background:

• The neurotrophin hypothesis links brain-derived neurotrophic factor (BDNF) to depression.
• The precise role of BDNF in depression's development and antidepressant action remains unclear.
• Predictive value of baseline serum BDNF for antidepressant response is unknown.

Purpose of the Study:

• To investigate serum BDNF levels in unmedicated depressed subjects compared to controls.
• To examine the effect of antidepressant treatment on serum BDNF levels.
• To determine if pre-treatment BDNF levels predict antidepressant response.

Main Methods:

• Thirty unmedicated depressed patients received escitalopram or sertraline for 8 weeks.
• Twenty-five patients completed treatment; 28 healthy controls were included.
• Serum BDNF levels and depression ratings were measured at baseline and after 8 weeks.

Main Results:

• Pre-treatment BDNF was lower in depressed subjects than controls (p=0.001).
• Antidepressant treatment increased BDNF levels (p=0.005) and improved depression ratings (p<0.001).
• Higher pre-treatment BDNF levels correlated with better antidepressant response (p<0.01).

Conclusions:

• Confirms lower serum BDNF in depression and antidepressant-induced increases.
• Suggests BDNF's role is facilitatory, not solely corrective, in antidepressant action.
• Pre-treatment BDNF levels are a significant predictor of antidepressant response.